TrovaGene, Inc. (NASDAQ:TROV) was down 10.5% during trading on Wednesday . The stock traded as low as $0.50 and last traded at $0.51. Approximately 574,089 shares changed hands during mid-day trading, an increase of 3% from the average daily volume of 558,335 shares. The stock had previously closed at $0.57.
Several equities research analysts recently commented on TROV shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of TrovaGene in a report on Tuesday, August 8th. Maxim Group set a $4.00 price objective on TrovaGene and gave the stock a “buy” rating in a report on Thursday, August 10th. Finally, downgraded TrovaGene from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th.
TrovaGene (NASDAQ:TROV) last released its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02. The business had revenue of $0.12 million during the quarter. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%.
ILLEGAL ACTIVITY NOTICE: “TrovaGene (TROV) Stock Price Down 10.5%” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/12/06/trovagene-trov-stock-price-down-10-5.html.
Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.
Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.